Available online 20 February 2023

The use of radioiodine (I-131) in the management of patients suffering differentiated thyroid cancer (DTC) has changed little in the past 40 years. The use of a standardized approach has served the majority of patients well over that time. However, there have been recent doubts concerning over this approach in some low risk patients and if so, how can these patients recognized and which patients who may need more intensive treatment.

A number of clinical trials have questioned the paradigms used in the treatment of DTC including what activity of I-131 should be used for ablation and which low risk patients should be treated with I-131 especially as there remains some doubts as to the long-term safety of I-131. Should a dosimetric approach be used to optimize the use of I-131 even though at present this approach has not been shown to improve outcomes in a formal clinical trial.

The era of precision oncology represents a challenge and opportunity to the nuclear medicine with a move away from a regime of standard care to one of highly individualized care based on the genetic profiling of the patient and their cancer. The treatment of DTC with I-131 is about to become very interesting.

© 2023 Elsevier Inc. All rights reserved.